Citations

Clear

3138 citation(s) found for "Smith, IC".

Establishment of an Early Pregnancy Care Clinic
Mussell, Megan E. V., Lamppa, Julie A., Smith, Rebecca M, Smith, R. Stephen

Mayo Clinic

Journal of Midwifery & Women's Health | April 16, 2026 | Volume: 71 | Issue: 4 | Pages: 652-656

10.1111/jmwh.70123 | PMID 41989136 Get It

Abstract Early pregnancy loss can have a profound impact on the lives of women and their families, but the experience is often underacknowledged, with the diverse and complex needs of these women not always being met. Health care providers are in a unique position to provide support, helping each woman navigate through what is often a significant event in her lifetime. In response to these gaps, a large academic medical center in the upper Midwest established the Early Pregnancy Care (EPC) Clinic in 2019 as a subclinic of the Department of Obstetrics and Gynecology. The goal of the EPC Clinic is to standardize the management of early pregnancy loss and related concerns to ensure each woman receives timely, holistic, and patient‐centered care that fully encompasses the physical and emotional needs of the patient and her family. The EPC Clinic is run by a small, dedicated team of certified nurse‐midwives and registered nurses in collaboration with a multidisciplinary team, providing comprehensive care to women with a confirmed early pregnancy loss, first trimester bleeding, pregnancy of unknown location, inconclusive viability, or a history of a prior early pregnancy loss, including ectopic and molar pregnancies. Team members coordinate timely visits and evaluation, offer comprehensive management options, and provide bereavement care and resources. Follow‐up care is arranged to monitor each woman's physical and emotional recovery following a loss, including check‐ins with consistent members of the team to maintain continuity of care. Anecdotal evidence as well as Press‐Ganey surveys obtained from patients and their families have demonstrated the exceptional value of the EPC Clinic. In this article, we outline our EPC Clinic's components and processes and discuss strategies that may benefit other health care systems aspiring to develop similar programs to improve early pregnancy loss care and the patient experience.
Historical outcomes for patients with stage IA NLPHL: Global NLPHL One Working Group retrospective analyses
Flerlage, Jamie E. , Eichenauer, Dennis A. , Fuchs, Michael, Hartmann, Sylvia , Eich, Hans Theodor, Savage, Kerry J. , Skinnider, Brian, Akhtar, Saad , Steiner, R., Milgrom, Sarah A., Vega, Francisco, Alomari, Mohammed , Zhang, Xiaoyin , Collins, Graham P., Advani, Ranjana H, Kumar, Priyadarshini , Wirth, Andrew, Tsang, Richard, Smith, SD, Hendrickson, Peter G. , Hopkins, David, McKay, Pamela, Ng, Andrea K. , Koenig, Julie L. , Sakthivel, Gukan, Baron, Jonathan A, Roberts, Kenneth B. , Gao, Sarah, Alkendi, Jalila , Rahbi, Nasser Al, Balogh, Alexander George, Ricardi, Umberto, Sridhar, Akshay, Torka, Pallawi , Specht, Lena , Silva, Ravi De , Shah, Nimish, Osborne, Wendy , Henry, Michael, Chang, Isabela , Halperin, Daniel, Miall, Fiona , Brady, J.L. , Mikhaeel, G., Brennan, Bernadette , Penn, Anthony, Reeves, Marie, Terezakis, Stephanie A, Pepa, R Della, Picardi, Marco, Kirova, Youlia, Fergusson, Paige, Hawkes, Eliza A. , Lee, Denise , Ku, Matthew , Hamad, Nada, Mutsando, Howard , Tedjaseputra, Aditya , Gilbertson, Michael, Marconi, Tamara , Viiala, Nicholas , Palese, Monica , Kelly, Kara M, Borchmann, P, Hoppe, Richard T. , Advani, Ranjana H. , Hopkins, David , Baron, Jonathan , Vega, Francisco , Kumar, Priyadarshini , Dickinson, Michael , Smith, Sonali M , McKay, Pamela , Koenig, Julie , Casulo, Carla , Al Kendi, Jalila , Levis, Mario , Torka, Pallawi , Specht, Lena , De Silva, Ravindu , Pickard, Keir , Smith, Christine M , Brady, Jessica , Senchenko, Maria Anatolevna , Volchkov, Egor Vasilevich , Hoppe, Bradford S , Hawkes, Eliza , Lee, Denise , Doo, Nicole Wong , Barraclough, Allison , Cheah, Chan Yoon , Salvaris, Ross , Ku, Matthew , Hamad, Nada , Tedjaseputra, Aditya , Shankar, Ananth , Maurer, Matthew , Natkunam, Yasodha , Hoppe, Richard T , Binkley, Michael Sargent , Savage, Kerry J , Advani, Ranjana H , Hopkins, David , Baron, Jonathan , Eichenauer, Dennis A , Flerlage, Jamie E , Fuchs, Michael, Eich, Hans Theodor, Hodgson, David C. , Skinnider, Brian, Rauf, M. Shahzad , Maghfoor, Irfan , Pinnix, Chelsea C. , Alomari, Mohammed, Collins, Graham P. , Dickinson, Michael , Tsang, Richard , Prica, Anca A. , Major, Ajay , Kelsey, Chris R. , Constine, Louis S , Casulo, Carla , Plastaras, John Peter , Balogh, Alexander G., Levis, Mario , Ricardi, Umberto , Sridhar, Akshay, Shah, Nimish , Pickard, Keir , Blazin, Lindsay , Henry, Michael, Smith, Christine M. , Hoppe, Bradford S. , Talaulikar, Dipti , Pepa, Roberta Della , Picardi, Marco , Kirova, Youlia , Northend, Michael , Doo, Nicole Wong , Barraclough, Allison , Opat, Stephen , Cheah, Chan Y. , Hamad, Nada , Gilbertson, Michael , Maurer, Matthew J. , Natkunam, Yasodha , Kelly, Kara M. , Borchmann, Peter , Binkley, Michael S.

Mayo Clinic

Blood Advances | April 14, 2026 | Volume: 10 | Issue: 15 | Pages: 5338-5347

10.1182/bloodadvances.2026020012 | PMID 41979337 Get It

Abstract We evaluated outcomes by management type for patients with stage IA nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL) in the Global NLPHL One Working Group retrospective database of 2243 patients with stages I to IV disease diagnosed from 1992 to 2021 at 38 international institutions. A total of 779 patients had stage IA disease with median age of 35 years (range, 3-89) and median follow-up of 6.1 years. The 6-year progression-free survival (PFS) and overall survival were 86.3% and 97.7%, respectively. Outcomes were analyzed for the 2 groups: complete resection and unresected disease. Patients with a complete resection and observation alone (n = 99) had a 6-year PFS of 65.5% vs 90.5% for those who received radiotherapy (RT) (n = 53). Patients with unresected disease (n = 627; 80.5%) had a 6-year PFS of 62.0% for rituximab alone (n = 31), 89.6% for RT alone (n = 325), 76.8% for ABVD (doxorubicin, bleomycin, vinblastine, dacarbazine) alone (n = 40), and 94.3% for ABVD plus RT (n = 130). A total of 127 patients relapsed (16.3%), of which 25 (19.7%) had transformation. Our analysis suggests the following: (1) RT improves the PFS in patients with completely resected disease; (2) rituximab or ABVD alone does not appear to achieve a durable response; and (3) chemotherapy was not observed to add additional PFS benefit when used in combination with RT. Thus, for stage IA NLPHL, RT alone is likely sufficient for definitive treatment.
Assessing the Utility of a Cosmetic Dermatology Journal Club
Chang, Joycie, Alvi, Saira , Zhang, Elizabeth, Smith, SJ, Gullapalli, Thanvi, Lazaro-Camp, Vanessa J, Dragovic, Doroteja, Ahmed, Areeba, Carter, Drake , Mills, Dawson , Henderson, Asia A., El-Khateeb, Hanin, Kang, Bianca Y. , Alam, Murad , Carter, Drake C , Ahmed, Areeba , Henderson, Asia

Mayo Clinic

Journal of Cosmetic Dermatology | April 14, 2026 | Volume: 25 | Issue: 4 | Pages: No page available

10.1111/jocd.70798 | PMID 41975526 Get It

ABSTRACT Background Journal clubs provide opportunities for discussion of new and evolving practices and technologies. Objective We sought to evaluate the utility and effectiveness of a monthly web‐based cosmetic dermatology journal club facilitated by faculty, residents, and medical students. Results From May 2025 to September 2025, 16 articles were discussed and 41 responses were recorded (response rate: 60%). Most respondents found the journal club was an appropriate length, engaging, and very useful. Relevance, frequency, and likelihood to participate in the future varied significantly by participant type. Medical students and residents collectively considered the journal club too infrequent ( p = 0.03) and reported it had less relevance to their practice ( p < 0.001). Conclusion A monthly web‐based cosmetic dermatology journal club was generally positively received by respondents.
Primary Care Clinicians’ Attitudes on Digital Care Collaborative Management for Substance Use Disorders
Lai, Benjamin , Bormann, N. L., Arndt, Stephan, Smith, Jamie, Stoppel, Cynthia , Tuen, Kelsey, Cox, Danielle, Breitinger, Scott , Williams, Mark, Paul, Margaret, Lai, Benjamin , Bormann, Nicholas L. , Arndt, Stephan , Paul, Margaret M. , Oesterle, Tyler

Mayo Clinic

INQUIRY: The Journal of Health Care Organization, Provision, and Financing | April 9, 2026 | Volume: 63 | Issue: No issue available | Pages: No page available

10.1177/00469580261440482 | PMID 41954165 Get It

Substance use disorders (SUD) remain a significant source of morbidity and mortality in the United States, and access to treatment continues to be inadequate. Primary Care Clinicians (PCCs) are well-positioned to provide long-term SUD care for patients. However, multiple provider-level barriers exist. Collaborative Care Management (CoCM) has proven successful in supporting PCCs in treating psychiatric conditions, such as depression. Our group proposes an addiction-focused modified CoCM that leverages telemedicine and an electronic platform (Senyo) into primary care. This study assesses PCCs’ attitudes toward this proposed model and their likelihood (with support) of prescribing medications for alcohol and opioid use disorder. To achieve this, an anonymized and confidential electronic survey was deployed to all 489 of our institutions’ PCCs. Eighty-five completed the survey (17.4% response); the majority (94%) agreed that digital CoCM for SUD will be helpful for their practice, and 85% expressed agreement that such a model will increase their confidence and likelihood to prescribe anti-craving medications. Additionally, we found that PCCs’ comfort level in addressing SUD with patients is not associated with years in practice, clinician type (attending physicians, resident/fellow physicians, nurse practitioner or physician assistant), or their perception of currently available SUD treatment resources. Future work to evaluate practice changes, including rates of anti-craving medication prescribing and SUD-treatment outcomes after implementation of our digital CoCM will prove useful in determining the effectiveness of this model.
Trends in Blood Pressure Control During the COVID‐19 Pandemic: A Study of 17 US Health Systems in the National Patient‐Centered Clinical Research Network Blood Pressure Control Laboratory
Chamberlain, Alanna M. , Cooper‐DeHoff, Rhonda M. , Fontil, Valy , Park, Soo , Shaw, Kathryn M., Smith, Myra C., Carton, Thomas W. , O'Brien, Emily C, Modrow, Madelaine Faulkner , Wozniak, Gregory , Smith, Steven M., Kappelman, M. D., Ford, D. Patrick, Williams, David A. , VanWormer, Jeffrey J. , Cowell, Lindsay G., Taylor, Bradley W., Chrischilles, EA, Carton, Thomas , O'Brien, Emily , Faulkner Modrow, Madelaine , Rakotz, Michael , Smith, Steven M , Kappelman, Michael D , Ford, Daniel E , Williams, David A , Reynolds Geary, Carol , Litvin, Cara , VanWormer, Jeffrey J , Mosa, Abu Saleh Mohammad , Taylor, Bradley , Chrischilles, Elizabeth A , Pletcher, Mark J , Chamberlain, Alanna M , Cooper‐DeHoff, Rhonda M. , Fontil, Valy , Park, Soo , Shaw, Kathryn M., O’Brien, Emily C. , Rakotz, Michael , Kappelman, Michael D. , Geary, Carol , Taylor, Bradley , Pletcher, Mark J.

Mayo Clinic

Journal of the American Heart Association | April 7, 2026 | Volume: 15 | Issue: 8 | Pages: No page available

10.1161/jaha.125.045694 | PMID 41944158 Get It

Background Reductions in blood pressure (BP) control among patients with hypertension were observed early in the COVID‐19 pandemic. The degree to which BP control may have returned to prepandemic levels is unknown. Methods Individuals aged 18 to 85 years with hypertension from 17 health systems participating in the National Patient‐Centered Clinical Research Network were identified using electronic health record data collected as part of routine care. BP control (percentage of patients whose most recent BP measurement was <140/<90 mm Hg) was estimated in a series of 12‐month rolling measurement periods from 2017 through 2022 (January 1, 2017 through December 31, 2017; April 1, 2017 through March 31, 2018; … January 1, 2022 through December 31, 2022). Differences in average BP control between 2022 (January 1, 2022 through December 31, 2022) and 2019 (January 1, 2019 through December 31, 2019) were estimated overall (adjusted for age, sex, and race and ethnicity) and by race and ethnicity (adjusted for age and sex). Results Our sample included 1 193 314 persons with hypertension in 2019 (48.9% aged 65–85 years, 52.9% men, 66.2% non‐Hispanic White) and 1 499 418 individuals in 2022 (50.6% aged 65–85 years, 47.1% men, 62.7% non‐Hispanic White). The weighted average BP control dropped from 65.3% in 2019 to 61.8% in 2020 and then partially recovered to 62.6% in 2022 (adjusted mean difference, −2.6 percentage points [95% CI, −5.0 to −0.2]). Non‐Hispanic Asian individuals experienced the largest temporal drop in BP control, declining from 68.4% in 2019 to 63.9% in 2022. Conclusions BP control was disrupted during the COVID‐19 pandemic and had not fully rebounded to prepandemic levels by the end of 2022. Continued surveillance is needed to determine whether the decline in BP control will persist and will result in future adverse cardiovascular events.
Toward actionable interventions in human aging (12th ARDD meeting, 2025)
Dekan, Aleksandr , Lore, Sierra , Yoon, Ye Eun, Sjöholm, Aisyah, Terskikh, Alexey V. , Cuervo, A. M., Georgievskaya, Anastasia , Heinz, Andrea , Adams, Andrew, Tsai, Andy P. , Murray, Anna, Brunet, Anne , Harten, Anne Marije van, Spier, Avi, Shenhar, Ben , Clasen, Berthil, Volbracht, Christiane , Kuppe, Christoph, Cookson, Clive, Banila, Cristiana , Cai, Daisy, Lamming, Dudley W. , Rudnic, Edward, Samra, Elias Bou , Verdin, Eric, Fagagna, Fabrizio d’Adda di, Zmudze, Garri, Jasper, Heinrich, Jang, In Hwa, Lemaitre, J. M., Betts-LaCroix, Joe , Newman, John C. , Kawamura, Kazuto , Schaal, Kennedy Matsagas, Egerton, Kitsu, Fortney, Kristen , Hartenstein, Lars, Niedernhofer, Laura, Katsimpardi, Lida , Melton, Lisa , Ferrucci, Luigi, Sylow, Lykke, Demaria, Marco , Guasch-Ferré, Marta, Borch-Jensen, Martin, Kholin, Maxim, Antonov, Michael, Deleidi, Michela , Mérad, Miriam , Meldal, Morten, Topors, Mourad, Venkatesan, Murali, LeBrasseur, Nathan K., Anzinger, Niklas, Fedichev, Peter O, Kohlhaas, Paul, Mullen, Peter J., Singhal, Priya , Cabo, Raquel, Montgomery, Rusty L. , Rosenzweig-Lipson, Sharon, Jakimov, Sergey, Austad, Steven N. , White, Todd, Zuber, Tom, Rozmaric, Tomaz , Wyss-Coray, Tony, Gladyshev, Vadim N., Sinatti, Vanessa V. C., Wang, Weilan, Harborne, William, Wang, Xing Li, Suh, Yousin , Lee, Y., Koch, Zane, Scheibye-Knudsen, Morten, Niedernhofer, Laura J. , Wyss‐Coray, Tony , Niedernhofer, Laura J , Lamming, Dudley W , Deleidi, Michela , Wyss-Coray, Tony , Bakula, Daniela , Tyshkovskiy, Alexander , Cuervo, Ana M , Seluanov, Andrei , Murray, Anna , Pedersen, Bente Klarlund , Schumacher, Björn , Kennedy, Brian Keith , Suetta, Charlotte , Kuppe, Christoph , Ewald, Collin Y. , Valenzano, Dario Riccardo , Rudnic, Edward M., Teeling, Emma C. , Verdin, Eric , Fang, Evandro Fei , Fagagna, Fabrizio d’Adda di , Galkin, Fedor , Jasper, Heinrich , Jang, In Hwa , Han, Jing‐Dong J. , Justice, Jamie N. , Hoeijmakers, Jan H.J. , Ramos, Javier María Peralta , Lemaı̂tre, Jean-Marc , Aerssens, Jeroen , Belmonte, Juan Carlos Izpisúa , Abdelmohsen, Kotb , Knudsen, Lotte Bjerre , Ferrucci, Luigi , Sylow, Lykke , Schafer, Marissa , Guasch‐Ferré, Marta , Levitt, Michael R. , Meldal, Morten , Fedichev, Peter O. , Mullen, Peter J. , Cabo, Rafael de, Houtkooper, Riekelt H. , Smith, Ryan , Rosenzweig‐Lipson, Sharon, Horvath, Steve , Rando, Thomas A. , White, Todd, Tammela, Tuomas , Gladyshev, Vadim N. , Sinatti, Vanessa V C , Liu, Xiaodong , Suh, Yousin , Koch, Zane , Zhavoronkov, Alex , Scheibye‐Knudsen, Morten

Mayo Clinic

Aging | April 6, 2026 | Volume: 18 | Issue: 1 | Pages: 282-302

10.18632/aging.206368 | PMID 41944812 Get It

Abstract 4560: CTPS1 as a metabolic vulnerability and novel therapeutic target in breast and ovarian cancer
Wang, Xiyin, Emch, Michael, Voll, Lauren, Epp, Rebecca, Rodman, Esther , Odell, Noa , Smith, Hannah , Pearson, Nicole A, Hou, X, Goetz, M. P., Weroha, S. John, Beer, Phillip, Hawse, John R., Emch, Michael J. , Kaufmann, Scott H. , Weroha, S. John

Mayo Clinic

Cancer Research | April 3, 2026 | Volume: 86 | Issue: 7_Supplement | Pages: 4560-4560

10.1158/1538-7445.am2026-4560 Get It

Abstract Breast and ovarian cancers are major causes of cancer mortality in women with frequent relapse after curative intent treatment, underscoring the need for novel therapeutics. To this end, we identified CTPS1 as an essential gene in multiple breast and ovarian cancer models, including those resistant to chemotherapy and PARP inhibitors. CTPS1 and CTPS2 are responsible for de novo synthesis of cytidine triphosphate (CTP) which is required for DNA/RNA polymerization, phospholipid synthesis and protein glycosylation. We found CTPS1 to be the predominant isoform expressed in cancer cells, with significantly higher levels in advanced and resistant disease models compared to normal tissue, benign lesions and treatment naïve cancers. Using CTPS1 siRNAs and CTPS1-dTAG (degradation tag) cell lines, we discovered that depletion of CTPS1 induces S-phase cell cycle arrest followed by apoptosis. Leveraging a first-in-class, highly selective, and orally bioavailable CTPS1 inhibitor (STP938) developed by Step Pharma, we identified nanomolar IC50 values across a panel of cell lines, both in 2D and 3D culture systems, and potent anti-neoplastic activity ex vivo and in vivo using patient-derived xenograft (PDX) models. STP938 also synergized with standard-of-care chemotherapy agents and PARP inhibitors, including in therapy-resistant models. Given the essentiality of CTP for biosynthetic processes, we performed bulk and single cell RNA-seq, total and phospho-proteomics, metabolomics, and lipidomic strategies to examine changes induced by acute and chronic STP938 exposure. This revealed that cancer cells are able to overcome pharmacologic CTPS1 inhibition by rewiring of pyrimidine and purine synthesis pathways, upregulation of the pentose phosphate pathway, and extensive remodeling of lipid synthesis pathways including shifts in PC/PE content, increased lysophospholipid production, and altered mitochondrial lipid composition (decreased cardiolipin and increased PG). To identify genetic drivers of STP938 resistance and synthetic lethal vulnerabilities, we performed a genome-wide CRISPR knockout screen together with a PRISM drug sensitivity screen. Genes regulating dNTP biosynthesis, S-phase progression, and RNA processing were identified as primary escape mechanisms, while DHODH inhibitors, purine and nucleoside analogs, and mitosis modifiers were implicated as synthetic lethal opportunities. Notably, we discovered that 25% of ovarian tumors lack CTPS2 protein expression, suggesting near complete reliance on CTPS1 for survival. Thus, a Phase 1a/b clinical trial of STP938 (NCT06297525) has been initiated, including an expansion cohort for patients with CTPS2-null ovarian tumors. These laboratory discoveries and ongoing clinical efforts aim to enable broader uptake of this novel therapeutic approach to improve long-term outcomes in patients with CTPS1-dependent disease. Citation Format: Xiyin Wang, Michael Emch, Lauren Voll, Rebecca Epp, Esther Rodman, Noa Odell, Hannah Smith, Nicole Pearson, Xiaonan Hou, Matthew Goetz, Scott Kaufmann, S. John Weroha, Phillip Beer, John Hawse. CTPS1 as a metabolic vulnerability and novel therapeutic target in breast and ovarian cancer [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2026; Part 1 (Regular Abstracts); 2026 Apr 17-22; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2026;86(7 Suppl):Abstract nr 4560.
Abstract 6544: Immune checkpoint inhibitor therapy in kidney transplant recipients: Real-world outcomes of antitumor activity and graft rejection risk
Roudkoli, Ali Rezazadeh , Barbir, Elena, Kavousi, Shahin , Aboelatta, Mohamed, Haivas, Claudia-Denise, Kukla, Aleksandra, Aboelatta, Mohamed A. , Smith, Byron H. , Kukla, Aleksandra , Dudek, Arkadiusz Z.

Mayo Clinic

Cancer Research | April 3, 2026 | Volume: 86 | Issue: 7_Supplement | Pages: 6544-6544

10.1158/1538-7445.am2026-6544 Get It

Abstract Background: Kidney transplant recipients (KTRs) have a markedly elevated risk of aggressive malignancies, yet the use of immune checkpoint inhibitors (ICIs) in this population remains limited by concerns for allograft rejection and the absence of prospective evidence. We evaluated real-world antitumor activity, graft safety, and immunosuppression-related outcomes of ICI therapy in KTRs with advanced cancers. Methods: We retrospectively analyzed 57 KTRs with locally advanced unresectable or metastatic malignancies treated between 2018-2025 at a single tertiary center. Thirty-three received ICIs and 24 received non-ICI systemic therapy. Outcomes included objective response rate (ORR), clinical benefit rate (CBR), progression-free survival (PFS), overall survival from diagnosis (OSd), overall survival from treatment initiation (OSt), acute allograft rejection, and immune-related adverse events (irAEs). Tumor response was assessed by RECIST v1.1. Results: ICI-treated patients achieved higher ORR (40.0% vs 26.1%) and CBR (60.0% vs 33.3%) compared with non-ICI therapy. Median OSd was 35.8 vs 23.3 months, and median PFS was 4.3 vs 3.5 months (both not statistically significant). Median OSt was significantly longer with ICIs (15.1 vs 7.9 months; p=0.012). Acute rejection occurred in 12.1% of ICI-treated patients (3% irreversible) versus 4.2% with systemic therapy; rejection events were heterogeneous in timing (3 weeks-14 months) and largely responsive to pulse-dose corticosteroids. IrAEs occurred in 27.3% of ICI patients, with grade ≥2 events in 12.1%, and no treatment-related deaths. In the cutaneous squamous cell carcinoma (cSCC) subgroup (n=33), ICI therapy produced an ORR of 47.4% and CBR of 63.2%, with trends toward improved survival relative to controls. Conclusions: ICIs produced clinically meaningful antitumor activity in KTRs, particularly in cSCC, with a manageable rate of allograft rejection under carefully tailored immunosuppression. Despite higher historical concerns, irreversible graft loss was uncommon. These findings support the feasibility of ICI therapy in selected transplant recipients and highlight the importance of immunosuppression strategy in balancing antitumor efficacy and graft safety. Prospective, biomarker-integrated studies are needed to define optimal immunosuppression during PD-1 blockade in this high-risk population. Citation Format: Ali Rezazadeh Roudkoli, Elena Barbir, Shahin Kavousi, Mohamed A. Aboelatta, Claudia-Denise Haivas, Byron H. Smith, Aleksandra Kukla, Arkadiusz Z. Dudek. Immune checkpoint inhibitor therapy in kidney transplant recipients: Real-world outcomes of antitumor activity and graft rejection risk [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2026; Part 1 (Regular Abstracts); 2026 Apr 17-22; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2026;86(7 Suppl):Abstract nr 6544.
Abstract 5547: Enhancing antibody-dependent cellular cytotoxicityin mesothelioma through concurrent EGFR and MET targeting withamivantamab
Suzuki, S., Parikh, K., Ayers-Ringler, Jennifer , Yang, Lin, Kosari, Farhad , Tolosa, Ezequiel J. , Wu, Kuan‐Li , Smith, Katherine E. , Mansfield, Aaron S.

Mayo Clinic

Cancer Research | April 3, 2026 | Volume: 86 | Issue: 7_Supplement | Pages: 5547-5547

10.1158/1538-7445.am2026-5547 Get It

Abstract Background: Diffuse pleural mesothelioma (DPM) is a highly aggressive malignancy with limited treatment options and poor prognosis. Although immune checkpoint inhibitors have improved outcomes, particularly for non-epithelioid subtypes, there remains no approved targeted therapy for mesothelioma. EGFR and MET are receptor tyrosine kinases frequently overexpressed in DPM, suggesting susceptibility to targeted antibody therapy. Amivantamab is a bispecific EGFR/MET antibody, originally developed for EGFR-mutant lung cancer, that blocks growth signals and engaging immune mechanisms. Given the high levels of EGFR and MET expression in mesothelioma, we evaluated the therapeutic potential of amivantamab in preclinical models. Methods: EGFR and MET transcript levels in DPM were analyzed using TCGA. Eight human mesothelioma cell lines were assessed by Western blotting and flow cytometry. Amivantamab binding, internalization, and signaling inhibition were examined using flow cytometry, confocal microscopy, and ligand-stimulated phosphorylation assays. Cytotoxicity and immune-effector activity were quantified using PBMCs, NK cells, and monocytes from healthy donors, along with an ADCC reporter assay. In vivo efficacy was tested in a DPM patient-derived xenograft (PDX) model in NOD/SCID-γ (NSG) mice supplemented with human NK cells and treated with amivantamab or control IgG. Results: TCGA analysis showed frequent EGFR/MET co-expression in DPM. Mesothelioma cell lines expressed higher EGFR and MET levels compared with mesothelial cells. Amivantamab strongly bound both receptors, induced receptor internalization, and inhibited EGF- and HGF-stimulated phosphorylation of EGFR, MET, and downstream AKT/ERK signaling. Direct cytotoxicity was minimal; however, the addition of PBMCs or NK cells resulted in robust, dose-dependent tumor cell killing consistent with antibody-dependent cellular cytotoxicity (ADCC). Reporter assays demonstrated 7-11-fold Fcγ receptor activation in tumor cells compared with ∼2-fold activation in non-malignant mesothelial cells. Co-culture with monocytes revealed amivantamab-induced trogocytosis, evidenced by loss of EGFR and MET from tumor-cell membranes. In the DPM PDX model, amivantamab produced 89.1% tumor-growth inhibition (TGI) relative to controls (P &lt; 0.0001), with no overt toxicity observed in treated mice. Conclusions: Dual EGFR/MET targeting with amivantamab produced potent antitumor effects in mesothelioma through coordinated receptor-signaling blockade, ADCC, and monocyte-mediated trogocytosis. These results support amivantamab as a promising targeted therapeutic strategy for EGFR/MET-positive DPM, particularly epithelioid subtypes that currently derive limited benefit from immunotherapy. Citation Format: Shinichiro Suzuki, Kaushal Parikh, Ezequiel Tolosa, Kuan-Li Wu, Jennifer Ayers-Ringler, Lin Yang, Katherine E. Smith, Farhad Kosari, Aaron S. Mansfield, . Enhancing antibody-dependent cellular cytotoxicityin mesothelioma through concurrent EGFR and MET targeting withamivantamab [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2026; Part 1 (Regular Abstracts); 2026 Apr 17-22; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2026;86(7 Suppl):Abstract nr 5547.
Abstract 2590: Urine cfDNA 4-mer end-motif signatures outperform other fragmentomic features for tissue-of-origin classification in genitourinary cancers
Linford, Jessica , Kim, Yohan, Panda, Arpit, Colon, Nathan, Mueller, Ryan , Qaium, Faridi , Reimers, Melissa A. , Smith, Zachary L. , Smelser, Woodson , Chaudhuri., Aadel A., Chauhan, Pradeep S. , Alahi, Irfan , Kim, Eric H. , Lucien, Fabrice , Chaudhuri, Aadel A.

Mayo Clinic

Cancer Research | April 3, 2026 | Volume: 86 | Issue: 7_Supplement | Pages: 2590-2590

10.1158/1538-7445.am2026-2590 Get It

Abstract Introduction: Urine cell-free DNA (cfDNA) is a promising ultra-noninvasive analyte for genitourinary cancers (GU) cancers. In this study, we investigated urine cfDNA fragmentomic features and evaluated their ability to predict the tumor tissue of origin. Methods: A total of 204 GU cancer patients and 34 healthy adults were enrolled in this prospective study. Preoperative urine was collected from 89 bladder cancer (BC) patients (64% muscle-invasive) undergoing cystectomy, 65 renal cell carcinoma (RCC) patients undergoing nephrectomy and 50 metastatic prostate cancer (mPC) patients. Urine cfDNA was isolated and sequenced at 5x genome-wide coverage on a NovaSeq S4 flow cell. To identify malignant tissue of origin, we analyzed somatic copy number alterations (CNAs), genome-wide fragment length ratios, and 4-mer end motifs. CNAs and tumor fraction (TFx) were quantified using ichorCNA in 1-Mb windows, while chromosome arm-level fragment count z-scores and fragment length ratios were calculated in 5-Mb bins across the genome. Relative frequencies of all 256 possible 4-mer end motifs were calculated for each sample. Individual logistic regression models were developed based on each fragmentomic feature using leave-one-out cross validation (LOOCV). Outputs from these models were combined into multi-feature XGBoost models. Cohort-specific end-motif enrichments were identified using Kruskal-Wallis tests with FDR correction. Motifs were then hierarchically clustered based on their cohort-wise median frequencies to define groups of motifs with shared fragmentation patterns. Results: Across urine cfDNA in the GU cohort, BC showed the highest mean TFx at 10.0%, followed by mPC at 3.6% and RCC at 2.7%. A machine learning model based on 4-mer end motifs achieved a mean ROC AUC of 0.933 with classification accuracies of 63% for healthy, 87% for BC, 72% for mPC, and 83% for RCC. This model outperformed models based on ichorCNA (AUC = 0.767), chromosome arm fragment-count z-scores (AUC = 0.827), and fragment length ratios (AUC = 0.674). Combining end motifs with other fragmentomic features did not improve prediction accuracy. Multi-feature models incorporating end motifs with ichorCNA, chromosome arm-level z-scores, or fragment-length ratios yielded mean AUCs between 0.908-0.924, lower than the end-motif only model. Kruskal-Wallis tests identified 179 of 256 end motifs (79%) as significantly different across healthy, BC, mPC, and RCC. Hierarchical clustering of cohort-level median motifs revealed distinct end motif patterns: Motifs beginning with CT were enriched in RCC; AAAA was strongly enriched in BC; and motifs beginning with CA, AC, and AG were enriched in mPC. Conclusion: Urine cfDNA 4-mer end motifs capture GU cancer-specific biological patterns that enable accurate tissue-of-origin prediction, underscoring their promise as a diagnostic tool. Citation Format: Jessica Linford, Pradeep S. Chauhan, Irfan Alahi, Yohan Kim, Arpit Panda, Nathan Colon, Ryan Mueller, Faridi Qaium, Eric H. Kim, Melissa A. Reimers, Zachary L. Smith, Woodson W. Smelser, Fabrice Lucien-Matteoni, Aadel A. Chaudhuri. Urine cfDNA 4-mer end-motif signatures outperform other fragmentomic features for tissue-of-origin classification in genitourinary cancers [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2026; Part 1 (Regular Abstracts); 2026 Apr 17-22; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2026;86(7 Suppl):Abstract nr 2590.